Home

CI — Deck

The Cigna Group · CI · NYSE

A $275B pharmacy-services giant disguised as a health insurer, trading at 9.3× trailing earnings

$277.56
Share Price
$74.1B
Market Cap
9.3×
Trailing P/E
$29.85
FY25 Adj. EPS
19% below 52-week high, 86% of revenue now from Evernorth, CEO Cordani retiring July 2026.
1 · Business

A pharmacy-services toll road with an insurance business bolted on

  • Evernorth Health Services ($235B rev). Express Scripts PBM plus Accredo specialty pharmacy — 2.2B claims/yr, 73% of pre-tax adjusted income at ~3.1% margins.
  • Cigna Healthcare ($47B rev). Employer medical benefits — 79% self-funded ASO (fees, no claims risk), 21% insured. Shrinking after the $4.9B Medicare Advantage sale to HCSC.
  • Scale economics. Top-3 Evernorth clients (incl. Centene ~19% of revenue) locked in through end of decade; $44.9B Express Scripts goodwill still anchors 28% of assets.
Moat is contract stickiness and claims volume — not brand. Amazon Pharmacy and rebate reform slowly erode it.
2 · Numbers

All-time-high adjusted EPS meets a decade-low multiple — the disconnect is the story

$29.85
FY25 Adj. EPS (was $20.47 in FY21)
$8.4B
FY25 Free Cash Flow (11.3% FCF yield)
263M
Shares Outstanding (was 341M in FY21, -23%)
84.4%
Medical Care Ratio (was 78.8% in FY22)

Adjusted EPS compounded ~10%/yr on a 23% share-count reduction and steady $8–10B FCF. Revenue tripled to $275B on Evernorth pharmacy pass-through, but MCR has climbed 560 bps in three years.

3 · People

B+ governance — 17-year CEO retiring July 2026, orderly internal succession

  • Cordani's exit. CEO since 2009 (750%+ TSR) retires July 1, 2026, becomes Executive Chair. Owns ~0.23% ($179M); $20.5M total comp, 70% equity-linked.
  • Evanko takes over. Current President & COO, ex-CFO — led Express Scripts integration finance and ran Cigna Healthcare. Rare CFO-plus-operator resume.
  • Low insider skin. Total insider ownership just 1.44% despite decades of equity grants; no meaningful open-market buying at 9× earnings is a notable absence.
  • Board & compliance. 9 of 10 directors independent with Lead Independent Director; still under a 5-year HHS-OIG Corporate Integrity Agreement through ~2028.
4 · Story

From diversified insurer to PBM-first platform — the pivot is nearly complete

2019–2023: The Great Simplification. Cigna methodically shed non-core assets — Group Disability & Life to New York Life (2020, $6.2B), international supplemental to Chubb (2022, $5.75B), and committed to exit Medicare Advantage — while doubling down on Evernorth. The Centene PBM win (~20M lives, effective 2024) cemented the pharmacy-first identity.

2024–2026: Reckoning & Reinvention. A $2.7B VillageMD write-down exposed capital-allocation weakness. FTC sued Express Scripts over insulin pricing (settled Feb 2026, no penalty but forced end to spread pricing). Management preemptively announced a rebate-free PBM model for 2027–28, completed the $4.9B HCSC Medicare sale, and invested $3.5B in Shields specialty pharmacy. Evernorth pre-tax margin compressed from 4.2% to 3.1%.

Credibility 7/10 — 5 straight years beating adj. EPS guidance, but VillageMD and MCR drift were poorly telegraphed.
5 · Web Intel

FTC settlement and rebate-free pivot create a 2026–27 earnings air pocket

  • FTC settlement (Feb 2026). Express Scripts must eliminate spread pricing, decouple rebates from list prices, and re-shore its Ascent GPO — no fine, but the traditional PBM model is effectively over.
  • Rebate-free rollout. Prime Therapeutics, DoD and Centene renewed at lower margins; TD Cowen cut target $387 → $333; consensus target drifted ~$370 → $338 (still 22% upside).
  • Bernstein upgrade (Mar 12, 2026). Moved to Outperform, calling the FTC and rebate-free announcements 'clearing events'; 18 of 23 analysts now rate CI Strong Buy.
Q1 2026 earnings late April — consensus $7.20 EPS. MCR stabilization is the single most-watched number.
6 · Risks

Three risks that could each reprice the stock 15–25%

  • MCR runaway. Medical care ratio at 84.4% and rising, driven by IFP losses. Above ~87% Cigna Healthcare's insured book earns nothing — forcing further exits and pure-PBM repricing.
  • PBM legislation. Federal bills pending to ban spread pricing and mandate 100% rebate pass-through; if enacted before the 2027–28 voluntary transition, Evernorth margin could dip below 2.5% and put $45B of Express Scripts goodwill at impairment risk.
  • Client concentration. Centene alone drives ~19% of external revenue; top-3 clients ~60% of Evernorth profits. Contract extends through end of decade, but any non-renewal is existential.
7 · What's Next

Three earnings prints and a CEO handoff before year-end — the air pocket gets priced in real time

  • Late Apr 2026 — Q1 2026 earnings. First print post-Medicare divestiture. MCR vs. the 83.7%–84.7% guide is the single number; stop-loss repricing comes into focus.
  • Jul 1, 2026 — CEO transition. Evanko takes over from Cordani; any strategic or capital-allocation reset signal moves the name more than the underlying number.
  • Jul 30, 2026 — Q2 2026 earnings (first under Evanko). Cleanest test of the reaffirmed $30.25 adj EPS floor and Evernorth pre-tax margin trajectory.
  • Oct 29, 2026 — Q3 2026 earnings. First concrete read on 2027 rebate-free client wins during open-enrollment season.
  • Nov 2026 — Investor Day (expected). Will the 10–14% long-term EPS algorithm be reaffirmed or walked down? Capital-return framework into 2027–28.
The Q2 2026 print is what the market will key on — first Evanko quarter plus first real look at rebate-free renewals.
8 · For & Against

Lean cautiously constructive — FCF-per-share math outweighs the MCR drift, but only just

  • For. Adj. EPS compounded $20.47 → $29.85 (FY21–FY25, ~10% CAGR) with a guide-beat every year, yet stock trades at 9.3× vs UNH at 15.8× (Quant, Historian).
  • For. $8.4B FCF on $74B cap = ~11% yield; share count down 23% to 263M; $10.3B buyback authorization left — FCF/share already $31.80 (Quant).
  • For. Feb 2026 FTC settlement closed with no fine; top-3 Evernorth clients locked through decade-end; Medicare divestiture done — most tail risks resolved favorably (Research, Historian).
  • Against. Evernorth pre-tax margin compressed 4.2% → 3.1% before rebate-free even hits P&L; TD Cowen cut target $387 → $333 (Warren, Research).
  • Against. MCR has drifted 78.8% → 84.4% over three years; 2026 guide of 83.7%–84.7% assumes the drift finally stops (Warren, Historian).
  • Against. $3.2B average annual GAAP-vs-adjusted gap; VillageMD $2.7B write-down wasn't flagged; compliance committee dissolved mid-CIA; insiders own just 1.44% and aren't buying (Sherlock, Historian).
My View — slight edge to the For side: 8.7× FCF/share with a shrinking denominator tips it. Flip to cautious if Q2 2026 Evernorth pre-tax margin prints below 2.8% and the 10–14% LT EPS algorithm gets walked down.

Watchlist to re-rate: Q2 2026 MCR inside 83.7%–84.7% guide, Evernorth pre-tax margin holding 3%+, federal PBM spread-pricing legislation progress.